SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

Schedule of segment revenues and profit

Segment revenues and profits were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(in millions)	2020		2019		2020		2019
Revenues:
Bausch + Lomb/International	$	1,169	$	1,175	$	3,166	$	3,501
Salix	496		551		1,377		1,505
Ortho Dermatologics	144		147		393		407
Diversified Products	329		336		878		964
	$	2,138	$	2,209	$	5,814	$	6,377
Segment profits:
Bausch + Lomb/International	$	336	$	333	$	830	$	989
Salix	360		375		968		995
Ortho Dermatologics	70		58		156		156
Diversified Products	248		246		634		714
	1,014		1,012		2,588		2,854
Corporate	(141)		(158)		(442)		(435)
Amortization of intangible assets	(391)		(475)		(1,263)		(1,452)
Asset impairments	(2)		(33)		(17)		(49)
Restructuring, integration and separation costs	(2)		(4)		(13)		(28)
Acquisition-related contingent consideration	(2)		(3)		(26)		(2)
Other expense, net	(16)		(10)		(146)		(15)
Operating income	460		329		681		873
Interest income	2		2		11		9
Interest expense	(374)		(406)		(1,155)		(1,221)
Loss on extinguishment of debt	—		—		(51)		(40)
Foreign exchange and other	(13)		9		(26)		12
Income (loss) before (provision for) benefit from income taxes	$	75	$	(66)	$	(540)	$	(367)

Schedule of revenues by segment and product category

Revenues by segment and product category were as follows:

	Three Months Ended September 30, 2020										Three Months Ended September 30, 2019
(in millions)	Bausch + Lomb/ International		Salix		Ortho Dermatologics		Diversified Products		Total		Bausch + Lomb/ International		Salix		Ortho Dermatologics		Diversified Products		Total
Pharmaceuticals	$	200	$	494	$	65	$	217	$	976	$	217	$	551	$	97	$	207	$	1,072
Devices	360		—		72		—		432		375		—		46		—		421
OTC	374		—		—		—		374		371		—		—		—		371
Branded and Other Generics	219		—		—		110		329		197		—		—		119		316
Other revenues	16		2		7		2		27		15		—		4		10		29
	$	1,169	$	496	$	144	$	329	$	2,138	$	1,175	$	551	$	147	$	336	$	2,209

	Nine Months Ended September 30, 2020										Nine Months Ended September 30, 2019
(in millions)	Bausch + Lomb/ International		Salix		Ortho Dermatologics		Diversified Products		Total		Bausch + Lomb/ International		Salix		Ortho Dermatologics		Diversified Products		Total
Pharmaceuticals	$	552	$	1,374	$	213	$	557	$	2,696	$	670	$	1,505	$	265	$	617	$	3,057
Devices	921		—		165		—		1,086		1,127		—		130		—		1,257
OTC	1,043		—		—		—		1,043		1,063		—		—		—		1,063
Branded and Other Generics	597		—		—		312		909		582		—		—		332		914
Other revenues	53		3		15		9		80		59		—		12		15		86
	$	3,166	$	1,377	$	393	$	878	$	5,814	$	3,501	$	1,505	$	407	$	964	$	6,377

Schedule of revenue attributed to a geographic region

Revenues are attributed to a geographic region based on the location of the customer and were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(in millions)	2020		2019		2020		2019
U.S. and Puerto Rico	$	1,301	$	1,369	$	3,522	$	3,851
China	94		85		231		275
Canada	87		85		244		252
Mexico	68		58		157		164
Egypt	59		55		175		157
Poland	57		53		168		168
Japan	57		67		159		181
France	42		45		131		156
Germany	32		33		108		119
Russia	32		47		89		124
Spain	21		18		53		62
United Kingdom	21		28		58		86
Other	267		266		719		782
	$	2,138	$	2,209	$	5,814	$	6,377

Schedule of customers that accounted for 10% or more of total revenue

Customers that accounted for 10% or more of total revenues were as follows:

	Nine Months Ended September 30,
	2020	2019
AmerisourceBergen Corporation	17%	17%
McKesson Corporation (including McKesson Specialty)	17%	17%
Cardinal Health, Inc.	13%	14%